This product is indicated for keratohelcosis and corneal injury due to various causes, corneal bum caused by acid or alkali, bullous keratitis, neuroparalytic keratitis, cornea and conjunctivae degenernation.
Promotes tear secretion in patients with dry eyes. Indicated for reduced tear secretion caused by ocular inflammation associated with keratoconjunctivitis sicca.
Sjogren’s syndrome, Stevens-Johnson syndrome, dry eye syndrome and other endogenous diseases; post-operative and drug-induced diseases, injury, discomfort caused by wearing contact lens and other exogenous diseases.
As an adjuvant therapy for cornea protection, this product is indicated for dry eye disease caused by various reasons (such as Sjogren’s syndrome, neuroparalytic keratitis, and exposure keratitis), conjunctiva and corneal irritations caused by the lack of tear film protection.
R & D and Innovation Drive the Company to Grow from Strength to Strength
Sinqi Ophthalmic Medications pursues innovation-driven growth and has a provincial-level enterprise technology center, a provincial-level ophthalmic medication engineering technology research center and a provincial-level child and adolescent myopia prevention and control engineering research center. It has also established an ophthalmic drug R & D platform for conventional ophthalmic preparations, instant gels, sustained-release preparations, compatibility testing for drug packaging materials, ophthalmic pharmacodynamics, pharmacokinetics, and toxicology, etc. It has developed a unique R&D system and has innovated in the forefront of ophthalmic medications.